Visual dysfunction in retinal and optic nerve disease

Neurologic Clinics

Volumn 21, Issue 2, 2003, Pages 445-481

  Murtha, Timothy ^a,b   Stasheff, Steven F ^c  

^a HARVARD MEDICAL SCHOOL   (United States)

^b JOSLIN DIABETES CENTER   (United States)

^c BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; AMANTADINE; AMIODARONE; ARSENIC DERIVATIVE; CHLORAMBUCIL; CHLOROQUINE; CHLORPROMAZINE; CHLORPROPAMIDE; CISPLATIN; CLOMIFENE; CYCLOSPORIN; DAPSONE; DEFEROXAMINE; DIGITALIS; DISULFIRAM; ETHAMBUTOL; HYDROXYCHLOROQUINE; INTERFERON; ISONIAZID; OKT 3; PENICILLAMINE; PHENOTHIAZINE DERIVATIVE; QUINIDINE; STREPTOMYCIN; SULFONAMIDE; TAMOXIFEN; THIORIDAZINE; TRICHLOROETHYLENE; UNINDEXED DRUG; VINCRISTINE;

BRIGHTNESS; COLOR VISION DEFECT; DIFFERENTIAL DIAGNOSIS; HUMAN; NIGHT BLINDNESS; OPTIC NERVE DISEASE; PERCEPTION DISORDER; PHOTOSENSITIVITY DISORDER; PRIORITY JOURNAL; RETINA DISEASE; RETINA MACULA AGE RELATED DEGENERATION; RETINA MACULA LUTEA; REVIEW; SCOTOMA; SYMPTOMATOLOGY; VISUAL ACUITY; VISUAL DISORDER; VISUAL FIELD DEFECT; VISUAL HALLUCINATION; VISUAL ILLUSION; VISUAL IMPAIRMENT; VITREOUS DISEASE;

EID: 0037799578     PISSN: 07338619     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0733-8619(02)00108-1     Document Type: Review

References (107)

1. Burde RM, Savino PJ, Trobe JD. Clinical decisions in neuro-ophthalmology. St. Louis: CV Mosby; 1985.
2. Barton JJS, Benatar M. The field of vision: a manual and atlas of perimetry. Humana Press, in press.
3. Berkow JW, Kelley JS, Orth DH, Fluorescein angiography. A guide to the interpretation of fluorescein angiograms. San Francisco: American Academy of Ophthalmology; 1984.
4. Puliafito CA, Hee MR, Schuman JS, et al. Optical coherence tomography of ocular diseases. Thorofare (NJ): Slack; 1995.
5. Russell R, Page N. Critical perfusion of brain and retina. Brain 1983;106:419-34.
6. Young LH, Appen RE. Ischemic oculopathy. A manifestation of carotid artery disease. Arch Neurol 1981;38(6):358-61.
7. Biousse V. Carotid disease and the eye. Curr Opin Ophthalmol 1997;8(6):16-26.
8. Carter JE. Chronic ocular ischemia and carotid vascular disease. Stroke 1985;16(4):721-8.
9. Hedges TR. The terminology of transient visual loss due to vascular insufficiency. Stroke 1984;15(5):907-8.
10. Wiebers DO, Swanson JW, Cascino TL, et al. Bilateral loss of vision in bright light. Stroke 1989;20(4):554-8.
11. Digre K, Corbett J. Idiopathic intracranial hypertension (pseudotumor cerebri): a reappraisal. Neurologist 2001;7:2-67.
12. Furlan AJ, Whisnant JP, Kearns TP. Unilateral visual loss in bright light. An unusual symptom of carotid artery occlusive disease. Arch Neurol 1979;36(11):675-6.
13. Goldberg RA, Goldey SH, Duckwiler G, et al. Management of cavernous sinus-dural fistulas. Indications and techniques for primary embolization via the superior ophthalmic vein. Arch Ophthalmol 1996;114(6):707-14.
14. Kosmorsky GS, Rosenfeld SI, Burde RM. Transient monocular obscuration-?amaurosis fugax: a case report. Br J Ophthalmol 1985;69(9):688-90.
15. WuDunn D, Zimmerman K, Sadun AA, et al. Comparison of visual function in fellow eyes after bilateral nonarteritic anterior ischemic optic neuropathy. Ophthalmology 1997;104(1):104-11.
16. Ischemic Optic Neuropathy Decompression Trial Study Group. Characteristics of patients with nonarteritic anterior ischemic optic neuropathy eligible for the Ischemic Optic Neuropathy Decompression Trial. Arch Ophthalmol 1996;114(11):1366-74.
17. Trobe J. The neurology of vision. Oxford (England): Oxford University Press; 2001.
18. De Potter P. Ocular manifestations of cancer. Curr Opin Ophthalmol 1998;9(6):100-4.
19. Glaser JS, Savino PJ, Sumers KD, et al. The photostress recovery test in the clinical assessment of visual function. Am J Ophthalmol 1977;83(2):255-60.
20. Haupert CL, Newman NJ. Prolonged Uhthoff phenomenon in sarcoidosis. Am J Ophthalmol 1997;124(4):564-6.
21. Miller N, Newman N. The essentials: Walsh & Hoyt's clinical neuro-ophthalmology. 5th edition. Baltimore: Williams & Wilkins; 1999.
22. Pascual J, Combarros O, Berciano J. Gaze-evoked amaurosis in pseudotumor cerebri. Neurology 1988;38(10):1654-5.
23. Bremner FD, Shallo-Hoffmann J, Riordan-Eva P, et al. Comparing pupil function with visual function in patients with Leber's hereditary optic neuropathy. Invest Ophthalmol Vis Sci 1999;40(11):2528-34.
24. Nikoskelainen EK, Huoponen K, Juvonen V, et al. Ophthalmologic findings in Leber hereditary optic neuropathy with special reference to mtDNA mutations. Ophthalmology 1996;103(3):504-14.
25. Letchavanakul A, Dechphongsaphilas W, Dhamcharee V. Leber's hereditary optic neuropathy. J Med Assoc Thai 1999;82(10):1051-5.
26. Nakamura M, Yamamoto M. Variable pattern of visual recovery of Leber's hereditary optic neuropathy. Br J Ophthalmol 2000;84(5):534-5.
27. Pezzi PP, De Negri AM, Sadun F, et al. Childhood Leber's hereditary optic neuropathy (ND1/3460) with visual recovery. Pediatr Neurol 1998;19(4):308-12.
28. Tran M, Bhargava R, MacDonald IM. Leber hereditary optic neuropathy, progressive visual loss, and multiple-sclerosis-like symptoms. Am J Ophthalmol 2001;132(4):591-3.
29. Giorgi D, Lagana B, Giorgi A, et al. Ischemic optic neuritis in Churg-Strauss syndrome. Recenti Prog Med 1997;88(6):273-5.
30. Oh KT, Oh DM, Hayreh SS. Optic disc vasculitis. Graefes Arch Clin Exp Ophthalmol 2000;238(8):647-58.
31. Hayreh SS, Podhajsky PA, Zimmerman B. Ocular manifestations of giant cell arteritis. Am J Ophthalmol 1998;125(4):509-20.
32. Newcomb RD. Acute, idiopathic blind spot enlargement syndrome. Optom Vis Sci 2000;77(4):178-87.
33. Volpe NJ, Rizzo JF 3rd, Lessell S. Acute idiopathic blind spot enlargement syndrome: a review of 27 new cases. Arch Ophthalmol 2001;119(1):59-63.
34. Fong KS, Fu ER. Multiple evanescent white dot syndrome-an uncommon cause for an enlarged blind spot. Ann Acad Med Singapore 1996;25(6):866-8.
35. Gass JD. Overlap among acute idiopathic blind spot enlargement syndrome and other conditions. Arch Ophthalmol 2001;119(11):1729-31.
36. Paul R, Gray R. Peripapillary lesions causing blind spot enlargement in a case of multiple evanescent white spot syndrome. Eye 1998;12(Pt 3a):482-4.
37. Pece A, Sadun F, Trabucchi G, et al. Indocyanine green angiography in enlarged blind spot syndrome. Am J Ophthalmol 1998;126(4):604-7.
38. Reddy CV, Brown J Jr, Folk JC, et al. Enlarged blind spots in chorioretinal inflammatory disorders. Ophthalmology 1996;103(4):606-17.
39. Rudnicka AR, Edgar DF. Automated static perimetry in myopes with peripapillary crescents-Part II. Ophthalmic Physiol Opt 1996;16(5):416-29.
40. Meyer JH, Guhlmann M, Funk J. Is the blind spot enlarged in early glaucoma? Eur J Ophthalmol 1998;8(1):28-32.
41. McKellar MJ, Hidajat RR, Elder MJ. Acute ocular methanol toxicity: clinical and electrophysiological features. Aust N Z J Ophthalmol 1997;25(3):225-30.
42. Jacobson DM, Adamus G. Retinal anti-bipolar cell antibodies in a patient with paraneoplastic retinopathy and colon carcinoma. Am J Ophthalmol 2001;131(6):806-8.
43. Wolf JE, Arden GB. Selective magnocellular damage in melanoma-associated retinopathy: comparison with congenital stationary nightblindness. Vision Res 1996;36(15):2369-79.
44. Thirkill CE, Keltner JL, Tyler NK, et al. Antibody reactions with retina and cancer-associated antigens in 10 patients with cancer-associated retinopathy. Arch Ophthalmol 1993;111(7):931-7.
45. Khawly JA, Rubin P, Petros W, et al. Retinopathy and optic neuropathy in bone marrow transplantation for breast cancer. Ophthalmology 1996;103(1):87-95.
46. Dukar O, Barr CC. Visual loss complicating OKT3 monoclonal antibody therapy. Am J Ophthalmol 1993;115(6):781-5.
47. Wu HM, Lee AG, Lehane DE, et al. Ocular and orbital complications of intraarterial cisplatin. A case report. J Neuroophthalmol 1997;17(3):195-8.
48. Nayfield SG, Gorin MB. Tamoxifen-associated eye disease. A review. J Clin Oncol 1996;14(3):1018-26.
49. Guyer DR, Tiedeman J, Yannuzzi LA, et al. Interferon-associated retinopathy. Arch Ophthalmol 1993;111(3):350-6.
50. Johnson MW, Vine AK. Hydroxychloroquine therapy in massive total doses without retinal toxicity. Am J Ophthalmol 1987;104(2):139-44.
51. Heckenlively JR, Martin D, Levy J. Chloroquine retinopathy. Am J Ophthalmol 1980;89(1):150-1.
52. Muttray A, Wolters V, Jung D, et al. Effects of high doses of toluene on color vision. Neurotoxicol Teratol 1999;21(1):41-5.
53. Fisher CM. Visual disturbances associated with quinidine and quinine. Neurology 1981;31(12):1569-71.
54. Keltner JL, Thirkill CE, Yip PT. Clinical and immunologic characteristics of melanoma-associated retinopathy syndrome: eleven new cases and a review of 51 previously published cases. J Neuroophthalmol 2001;21(3):173-87.
55. Mizener JB, Kimura AE, Adamus G, et al. Autoimmune retinopathy in the absence of cancer. Am J Ophthalmol 1997;123(5):607-18.
56. Ludwig IH, Zegarra H, Zakov ZN. The acute retinal necrosis syndrome. Possible herpes simplex retinitis. Ophthalmology 1984;91(12):1659-64.
57. Freeman CY, Forrester BD, Chappell WA, et al. Demonstration of herpes group virus in acute retinal necrosis syndrome. J Clin Microbiol 1986;24(4):527-31.
58. Holopigian K, Greenstein V, Seiple W, et al. Rates of change differ among measures of visual function in patients with retinitis pigmentosa. Ophthalmology 1996;103(3):398-405.
59. Blamires TL, Reeves BC. Vision defects in patients with peri-chiasmal lesions. Optom Vis Sci 1996;73(9):572-8.
60. Frohman LP, Frieman BJ, Wolansky L. Reversible blindness resulting from optic chiasmitis secondary to systemic lupus erythematosus. J Neuroophthalmol 2001;21(1):18-21.
61. The Optic Neuritis Study Group. Visual function 5 years after optic neuritis: experience of the Optic Neuritis Treatment Trial. Arch Ophthalmol 1997;115(12):1545-52.
62. Cleary PA. Visual symptoms after optic neuritis. Results from the Optic Neuritis Treatment Trial. J Neuro-Ophthalmol 1997;17(1):18-23; quiz 24-18.
63. Morales DS, Siatkowski RM, Howard CW, et al. Optic neuritis in children. J Pediatr Ophthalmol Strabismus 2000;37(5):254-9.
64. Ewing FM, Deary IJ, Strachan MW, et al. Seeing beyond retinopathy in diabetes: electrophysiological and psychophysical abnormalities and alterations in vision. Endocr Rev 1998;19(4):462-76.
65. Alexander KR, Fishman GA, Derlacki DJ. Intraocular light scatter in patients with retinitis pigmentosa. Vision Res 1996;36(22):3703-9.
66. D'Ambrosio FA Jr. Assessing disability in the patient with cataracts. Curr Opin Ophthalmol 1999;10(1):42-5.
67. Lee YC, Kim HS. Clinical symptoms and visual outcome in patients with presumed congenital cataract. J Pediatr Ophthalmol Strabismus 2000;37(4):219-24.
68. Steinert RF. Visual outcomes with multifocal intraocular lenses. Curr Opin Ophthalmol 2000;11(1):12-21.
69. Haring G, Dick HB, Krummenauer F, et al. Subjective photic phenomena with refractive multifocal and monofocal intraocular lenses. Results of a multicenter questionnaire. J Cataract Refract Surg 2001;27(2):245-9.
70. Batra VN, McLeod SD. Phakic intraocular lenses. Ophthalmol Clin North Am 2001;14(2):335-8, viii.
71. Haw WW, Manche EE. Effect of preoperative pupil measurements on glare, halos, and visual function after photoastigmatic refractive keratectomy. J Cataract Refract Surg 2001;27(6):907-16.
72. Ellerton CR, Krueger RR. Postoperative complications of excimer laser photorefractive keratectomy for myopia. Ophthalmol Clin North Am 2001;14(2):359-76, ix.
73. Mackie SW, Walsh G. Contrast and glare sensitivity in diabetic patients with and without pan-retinal photocoagulation. Ophthalmic Physiol Opt 1998;18(2):173-81.
74. Mantyjarvi M, Tuppurainen K, Ikaheimo K. Ocular side effects of amiodarone. Surv Ophthalmol 1998;42(4):360-6.
75. Bessant DA, Hameed A. Molecular genetics and prospects for therapy of the inherited retinal dystrophies. Curr Opin Genet Dev 2001;11(3):307-16.
76. Wang Q. Update on the molecular genetics of retinitis pigmentosa. Invest Ophthalmol Vis Sci 2001;42(7):1436-8.
77. Sherman J, Richter SJ, Epstein A. The differential diagnosis of visual disorders in patients presenting with marked symptoms but with no observable ocular abnormality. Am J Optom Physiol Opt 1980;57(8):516-22.
78. Grant CA, Berson EL. Treatable forms of retinitis pigmentosa associated with systemic neurological disorders. Int Ophthalmol Clin 2001;41(1):103-10.
79. Berson EL. Retinitis pigmentosa and allied diseases. In: Albert DM, Jokobiec FA, editors. Principles and practice of ophthalmology. Philadelphia: W.B. Saunders; 1994. p. 1214-37.
80. Feigl B, Faschinger C, Soyer P. Melanoma-associated retinopathy versus abnormal retinal function due to interferon-alpha/isotretinoin therapy in cutaneous malignant melanoma. Ophthalmologica 2000;214(4):271-6.
81. Lakhanpal V, Schocket SS, Jiji R. Deferoxamine (Desferal)-induced toxic retinal pigmentary degeneration and presumed optic neuropathy. Ophthalmology 1984;91(5):443-51.
82. American Academy of Ophthalmology. Age-related macular degeneration preferred practice pattern. San Francisco: American Academy of Ophthalmology; 1998.
83. Koch F, Augustin AJ, Boker T: neuroborreliosis with retinal pigment epithelium detachments. Ger J Ophthalmol 1996;5(1):12-5.
84. Reed JB, Scales DK, Wong MT, et al. Bartonella henselae neuroretinitis in cat scratch disease. Diagnosis, management, and sequelae. Ophthalmology 1998;105(3):459-66.
85. Grover S. Visual acuity impairment in patients with retinitis pigmentosa. Ophthalmology 1996;103(10):1593-600.
86. Grover S, Fishman GA, Anderson RJ, et al. Visual acuity impairment in patients with retinitis pigmentosa at age 45 years or older. Ophthalmology 1999;106(9):1780-5.
87. Mermoud A, Safran AB, de Stoutz N. Pain upon eye movement following digoxin absorption. J Clin Neuroophthalmol 1992;12(1):41-2.
88. Piltz JR, Wertenbaker C, Lance SE, et al. Digoxin toxicity. Recognizing the varied visual presentations. J Clin Neuroophthalmol 1993;13(4):275-80.
89. Noureddin BN, Seoud M, Bashshur Z, et al. Ocular toxicity in low-dose tamoxifen: a prospective study. Eye 1999;13(Pt 6):729-33.
90. Reichel E. Hereditary cone dysfunction syndromes. In: Albert DM, Jakobiec FA, editors. Principles and practice of ophthalmology. Philadelphia: W.B. Saunders; 1994. p. 1238-49.
91. Nathans J. The evolution and physiology of human color vision: insights from molecular genetic studies of visual pigments. Neuron 1999;24(2):299-312.
92. Schneck ME, Haegerstrom-Portnoy G. Color vision defect type and spatial vision in the optic neuritis treatment trial. Invest Ophthalmol Vis Sci 1997;38(11):2278-89.
93. Votruba M, Fitzke FW, Holder GE, et al. Clinical features in affected individuals from 21 pedigrees with dominant optic atrophy. Arch Ophthalmol 1998;116(3):351-8.
94. Onder F, Ilker S, Kansu T, et al. Acute blindness and putaminal necrosis in methanol intoxication. Int Ophthalmol 1998;22(2):81-4.
95. Sivakumaran P, Harrison AC, Marschner J, et al. Ocular toxicity from ethambutol: a review of four cases and recommended precautions. N Z Med J 1998;111(1077):428-30.
96. Mojon DS, Rosler KM, Oetliker H. A bedside test to determine motion stereopsis using the Pulfrich phenomenon. Ophthalmology 1998;105(7):1337-44.
97. Chylack LT, Friend J, Burns SA. Prediction of postoperative visual function in cataract patients. In: Albert OM, Jokobiec FA, editors. Principles and practice of ophthalmology. Philadelphia: W.B. Saunders; 1994. p. 678-9.
98. Moore RF. Subjective lightning streaks. Br J Ophthalmol 1935;19:545-7.
99. Nebel BR. The phosphene of quick eye motion. Arch Ophthalmol 1957;58:235-43.
100. Davis FA, Bergen D, Schauf C, et al. Movement phosphenes in optic neuritis: a new clinical sign. Neurology 1976;26(11):1100-4.
101. Page NG, Bolger JP, Sanders MD. Auditory evoked phosphenes in optic nerve disease. J Neurol Neurosurg Psychiatry 1982;45(1):7-12.
102. Lessell S, Cohen MM. Phosphenes induced by sound. Neurology 1979;29(11):1524-6.
103. Jacobs L, Karpik A, Bozian D, et al. Auditory-visual synesthesia: sound-induced photisms. Arch Neurol 1981;38(4):211-6.
104. Purvin VA. Visual disturbance secondary to clomiphene citrate. Arch Ophthalmol 1995;113(4):482-4.
105. Horton JC, Trobe JD. Akinetopsia from nefazodone toxicity. American Journal of Ophthalmology 1999;128(4):530-1.
106. Pomeranz HD, Lessell S. Palinopsia and polyopia in the absence of drugs or cerebral disease. Neurology 2000;54(4):855-9.
107. Bonnet C. Essai analytique sur les facultes de l'ame, 2nd edition. Coppenhagen: C. & A. Philibert; 1769.